Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$262.75 - $319.31 $24.6 Million - $29.9 Million
-93,600 Reduced 93.23%
6,800 $2.12 Million
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $23 Million - $27.7 Million
85,400 Added 569.33%
100,400 $28.5 Million
Q4 2023

Feb 14, 2024

BUY
$255.7 - $288.46 $3.84 Million - $4.33 Million
15,000 New
15,000 $4.32 Million
Q1 2023

May 15, 2023

BUY
$225.79 - $275.2 $56.4 Million - $68.8 Million
250,000 New
250,000 $60.4 Million
Q1 2021

May 14, 2021

SELL
$221.91 - $258.6 $11.6 Million - $13.5 Million
-52,300 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$216.38 - $257.67 $11.3 Million - $13.5 Million
52,300 New
52,300 $12 Million
Q3 2020

Nov 13, 2020

SELL
$234.65 - $260.95 $8.56 Million - $9.52 Million
-36,500 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$197.81 - $242.74 $27.2 Million - $33.3 Million
-137,300 Reduced 79.0%
36,500 $523,000
Q1 2020

May 14, 2020

BUY
$182.24 - $241.7 $15.2 Million - $20.2 Million
83,500 Added 92.47%
173,800 $35.2 Million
Q3 2019

Nov 13, 2019

BUY
$174.11 - $208.62 $15.7 Million - $18.8 Million
90,300 New
90,300 $17.5 Million
Q2 2019

Aug 13, 2019

SELL
$166.7 - $195.41 $6.67 Million - $7.82 Million
-40,000 Closed
0 $0
Q1 2019

May 08, 2019

SELL
$180.87 - $203.88 $11.2 Million - $12.6 Million
-61,700 Reduced 60.67%
40,000 $7.6 Million
Q4 2018

Feb 14, 2019

SELL
$178.4 - $208.25 $28.9 Million - $33.7 Million
-161,900 Reduced 61.42%
101,700 $19.8 Million
Q1 2018

May 14, 2018

BUY
$169.43 - $198.0 $19.6 Million - $22.9 Million
115,800 Added 78.35%
263,600 $44.9 Million
Q4 2017

Feb 13, 2018

SELL
$168.79 - $188.59 $18.7 Million - $20.9 Million
-111,000 Reduced 42.89%
147,800 $25.7 Million
Q3 2017

Nov 13, 2017

BUY
$167.29 - $191.0 $43.3 Million - $49.4 Million
258,800
258,800 $48.3 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $158B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Laurion Capital Management LP Portfolio

Follow Laurion Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Laurion Capital Management LP with notifications on news.